EGFR inhibitor, preparation method and use thereof

US10428081B2 · kind B2 · utility

Assignees

• SHANGHAI HANSOH BIOMEDICAL CO., LTD · CN
• JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD · CN

Inventors

• Mingsong Wei · Shanghai, CN
• Guangjun Sun · Shanghai, CN
• Songliang Tan · 安丰镇, CN
• Peng Gao · Nanhu, CN
• Shaobao Wang · 安丰镇, CN
• Wenhua Xiu · Shanghai, CN
• Fujun Zhang · Hangzhou City, CN
• Rudi Bao · 安丰镇, CN

Key dates

• Filing date: Dec 3, 2018
• Grant date: Oct 1, 2019
• Expiry date: Dec 3, 2038

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02P20/55
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Epidermal growth factor receptor (EGFR) inhibitors are provided. In particular, 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I), a preparation method and use thereof as an EGFR inhibitor are provided. The 4-substituted-2-(N-(5-substituted ally amide)phenyl)amino)pyrimidine derivatives of formula (I) have inhibitory activity against the L858R EGFR mutant, the T790M EGFR mutant and the exon 19 deletion activating mutant, and can be used to treat diseases mediated alone or in part by EGFR mutant activity. The derivatives of formula (I) can be used to treat and/or prevent cancers, particularly non-small cell lung cancer.